|
|
Volumn 11, Issue 6, 2011, Pages 841-843
|
|
Defining the role of the immune system in cancer treatment: Highlights from the Immunochemotherapy Conference
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENOSINE TRIPHOSPHATE;
ANTHRACYCLINE;
ANTINEOPLASTIC AGENT;
CALRETICULIN;
CYCLOPHOSPHAMIDE;
HIGH MOBILITY GROUP B1 PROTEIN;
INTERLEUKIN 17;
OXALIPLATIN;
PACLITAXEL;
PLX 3397;
TOLL LIKE RECEPTOR AGONIST;
UNCLASSIFIED DRUG;
APOPTOSIS;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CANCER IMMUNOTHERAPY;
CANCER RADIOTHERAPY;
CANCER STAGING;
CARCINOGENESIS;
CD8+ T LYMPHOCYTE;
CONFERENCE PAPER;
CYTOTOXIC T LYMPHOCYTE;
DRUG POTENTIATION;
ENDOPLASMIC RETICULUM STRESS;
EVIDENCE BASED MEDICINE;
HUMAN;
IMMUNE RESPONSE;
IMMUNE SYSTEM;
IMMUNOGENICITY;
IMMUNOSUPPRESSIVE TREATMENT;
INNATE IMMUNITY;
LOW DRUG DOSE;
MOLECULAR DYNAMICS;
NONHUMAN;
OVARY CARCINOMA;
PANCREAS CARCINOMA;
PERSONALIZED MEDICINE;
PREDICTION;
SIGNAL TRANSDUCTION;
T CELL DEPLETION;
TH2 CELL;
TUMOR MICROENVIRONMENT;
ANIMALS;
ANTINEOPLASTIC AGENTS;
DISEASE PROGRESSION;
HUMANS;
IMMUNE SYSTEM;
NEOPLASMS;
TREATMENT OUTCOME;
|
|
EID: 79959788642
PISSN: 14737140
EISSN: 17448328
Source Type: Journal
DOI: 10.1586/era.11.57 Document Type: Conference Paper |
|
Times cited : (2)
|
|
References (3)
|
